Photodynamic therapy with aminolevulinic acid and blue light is used in Europe for basal cell carcinoma (BCC), but not in the United States due to uncertainties about efficacy. To potentially improve treatment outcomes and make PDT a more attractive as therapy for BCC, we conducted a prospective, double-blind, crossover clinical trial to test whether pretreatment with oral Vitamin D may enhance BCC responses to blue light PDT. Three separate PDT sessions were administered, with patients receiving daily doses of Vitamin D (10,000 units) or placebo for a week prior to PDT. We will report here on interim clinical trial outcomes.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.